SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
Preventing HIV and HSV-2: What Will It Take?
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
9 of
9
|
Pragmatic Open-Label Randomised Trial of Preexposure Prophylaxis: The PROUD Study
Sheena McCormack
MRC Clinical Trials Unit at University College London, London, United Kingdom
On Demand PrEP With Oral TDF-FTC in MSM: Results of the ANRS Ipergay Trial
Jean-Michel Molina
University of Paris Diderot, Paris, France
Near Elimination of HIV Transmission in a Demonstration Project of PrEP and ART
Jared Baeten
University of Washington, Seattle, WA, United States
Scale-Up of Preexposure Prophylaxis in San Francisco to Impact HIV Incidence
Robert M. Grant
Gladstone Institutes, San Francisco, CA, United States
FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women
Helen Rees
Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
Effect of Oral and Gel Tenofovir on Genital HSV Shedding in Immunocompetent Women
Rachel A. Bender Ignacio
University of Washington, Seattle, WA, United States
Injectable Hormonal Contraception Use and Women's Risk for HSV-2 Acquisition
Mary K. Grabowski
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States
Effect of Financial Incentives on Linkage to Care and Viral Suppression: HPTN 065
Wafaa M. El-Sadr
ICAP at Columbia University, New York, NY, United States
Medical Male Circumcision of HIV-Infected Men Reduces Long-Term Penile HIV Shedding
Jordyn L. Manucci
Johns Hopkins University School of Medicine, Baltimore, MD, United States
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
9 of
9
|
